Literature DB >> 15502649

The HaP-T1 Syrian golden hamster pancreatic cancer model: cell implantation is better than tissue implantation.

Ajit T Abraham1, Sudeep R Shah, Brian R Davidson.   

Abstract

OBJECTIVES: Pancreatic cancer is characterized by a poor prognosis and an unsatisfactory response to conventional therapy. Appropriate experimental animal models that mimic the disease are essential to establish new therapies. The aim of this study was to compare homologous orthotopic cell implantation (OCI) and orthotopic tissue implantation (OTI) methods in the nitrosamine-derived HaP-T1 Syrian golden hamster pancreatic cancer model.
METHODS: Pancreatic tumors were induced in 32 Syrian hamsters by the OCI (n = 16) and OTI (n = 16) techniques. OTI and OCI subgroups (n = 4) were killed at 1, 2, 5, and 8 weeks post-implantation. Tumor uptake and growth and the rates of local invasion and metastases were compared at autopsy.
RESULTS: Tumor uptake was 100% by OCI and 88% by OTI. Induced pancreatic tumors were significantly larger in the OCI group (mean weight, 1.7 g vs. 0.26 g, P < 0.01.) The incidence of local invasion and rates of lymph node, liver, and peritoneal metastases were all significantly higher in the OCI group.
CONCLUSION: The OCI method is more effective than OTI in terms of tumor uptake. Tumor growth and the rates of local invasion and spontaneous metastases are higher with OCI than OTI. The OCI method is better than OTI and can contribute to the development of therapeutic strategies in pancreatic cancer research.

Entities:  

Mesh:

Year:  2004        PMID: 15502649     DOI: 10.1097/00006676-200411000-00012

Source DB:  PubMed          Journal:  Pancreas        ISSN: 0885-3177            Impact factor:   3.327


  6 in total

1.  Development of an orthotopic model of invasive pancreatic cancer in an immunocompetent murine host.

Authors:  William W Tseng; Daniel Winer; Justin A Kenkel; Okmi Choi; Alan H Shain; Jonathan R Pollack; Randy French; Andrew M Lowy; Edgar G Engleman
Journal:  Clin Cancer Res       Date:  2010-06-09       Impact factor: 12.531

2.  Safety and antitumor effect of oncolytic and helper-dependent adenoviruses expressing interleukin-12 variants in a hamster pancreatic cancer model.

Authors:  J Poutou; M Bunuales; M Gonzalez-Aparicio; E Garcia-Aragoncillo; J I Quetglas; R Casado; C Bravo-Perez; P Alzuguren; R Hernandez-Alcoceba
Journal:  Gene Ther       Date:  2015-05-04       Impact factor: 5.250

3.  Orthotopic Models of Pancreatic Cancer to Study PDT.

Authors:  Girgis Obaid; Zhiming Mai; Tayyaba Hasan
Journal:  Methods Mol Biol       Date:  2022

4.  Experimental Models in Syrian Golden Hamster Replicate Human Acute Pancreatitis.

Authors:  Yunan Wang; Abudurexiti Kayoumu; Guotao Lu; Pengfei Xu; Xu Qiu; Liye Chen; Rong Qi; Shouxiong Huang; Weiqin Li; Yuhui Wang; George Liu
Journal:  Sci Rep       Date:  2016-06-15       Impact factor: 4.379

5.  Re-designing Interleukin-12 to enhance its safety and potential as an anti-tumor immunotherapeutic agent.

Authors:  Pengju Wang; Xiaozhu Li; Jiwei Wang; Dongling Gao; Yuenan Li; Haoze Li; Yongchao Chu; Zhongxian Zhang; Hongtao Liu; Guozhong Jiang; Zhenguo Cheng; Shengdian Wang; Jianzeng Dong; Baisui Feng; Louisa S Chard; Nicholas R Lemoine; Yaohe Wang
Journal:  Nat Commun       Date:  2017-11-09       Impact factor: 14.919

6.  Enhanced therapeutic effect using sequential administration of antigenically distinct oncolytic viruses expressing oncostatin M in a Syrian hamster orthotopic pancreatic cancer model.

Authors:  Estanislao Nistal-Villan; Maria Bunuales; Joanna Poutou; Manuela Gonzalez-Aparicio; Carlos Bravo-Perez; Jose I Quetglas; Beatriz Carte; Gloria Gonzalez-Aseguinolaza; Jesus Prieto; Esther Larrea; Ruben Hernandez-Alcoceba
Journal:  Mol Cancer       Date:  2015-12-16       Impact factor: 27.401

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.